


available on the web
www.produ.com/journals

Drugs of the future.
v. 24, no. 7 (July 1999)
General Collection
W1 DR897
Received: 10-01-1999


Volume 24, Number 7, July 1999

Drugs of the Future

000006	DRUGS OF THE FUTURE
09906073901022	1999 VOLUME 24 ISSUE 7
09906073901022	SISAC
09906073901022	0377-8282(1999)24:7;1-S
SWETS	W1 DR897
	S032533/01
	02110369

 PROPERTY OF THE
NATIONAL
LIBRARY OF
MEDICINE

NATIONAL INSTITUTE OF HEALTH



Monographs

- 725 Dexloxyglumide. *CCK₁ (CCK_A) receptor antagonist, Treatment of irritable bowel syndrome.*
L. Revel, F. Makovec, J. Castañer
- 729 Prucalopride. *5-HT₄ agonist, Treatment of irritable bowel syndrome.* X. Rabasseda, J. Castañer
- 735 Raxofelast. *Treatment of diabetic complications, Antioxidant.* S. Cuzzocrea, S. Ceccarelli
- 740 Robalzotan Tartrate Hydrate. *Antidepressant, 5-HT_{1A} antagonist.* L.A. Sorbera, P. Leeson, J. Castañer
- 747 Weige. *Treatment of erectile dysfunction.* X-W. Wang

Review Articles

- 751 Indole-containing thiazolidine-2,4-diones as novel euglycemic and hypolipidemic agents
B.B. Lohray, V. Bhushan
- 759 P2Y₂ receptor agonists: structure, activity and therapeutic utility
B.R. Yerxa, F.L. Johnson
- 771 Progress in the design of inhibitors of coagulation factor Xa
W.R. Ewing, H.W. Pauls, A.P. Spada

Information Update 1-23

- | | | | |
|-----|--------------------------|-----|----------------------------|
| 790 | 1263W94 | 808 | Metazosin |
| 790 | Acreozast | 808 | MKC-442 |
| 791 | Azelnidipine | 809 | Moguisteine |
| 791 | Basiliximab | 809 | Nifedipine |
| 792 | Bucindolol Hydrochloride | 810 | Oltipraz |
| 792 | C-1311 | 810 | Pentostatin |
| 793 | Celecoxib | 810 | Phentolamine Mesilate |
| 796 | Ceterizine Hydrochloride | 811 | Raloxifene Hydrochloride |
| 797 | Daptomycin | 815 | Ramoplanin |
| 798 | DMP-754 | 815 | Repaglinide |
| 799 | Ebastine | 820 | Risedronate Sodium |
| 800 | Entacapone | 821 | Ritonavir |
| 801 | Fosphenytoin Sodium | 821 | Rivastigmine |
| 801 | Frovatriptan | 823 | Rizatriptan Benzoate |
| 804 | Idoxifene | 825 | Saredutant |
| 806 | Idoxuridine | 825 | Thrombopoietin |
| 806 | Imidapril Hydrochloride | 827 | Tolteridone |
| 806 | Ipsapirone | 827 | Triptolide |
| 807 | KE-298 | 829 | Valaciclovir |
| 808 | Levofloxacin | 830 | Vatanidipine Hydrochloride |
| | | 830 | Zileuton |

Drugs of the Future

Drugs of the Future is Published monthly. A Pharmacostructural index appears annually in the December issue. Cumulative chemical formula and general indices are published separately every year.

Subscription Rates

Calendar year subscription price for Volume 24, 1999 is US \$ 1015. Airmail additional (optional): America \$ 70, Asia \$ 120, Europe \$ 40. Back volumes are available in book form, offering an Encyclopedia of drugs in various stages of research, continuously updated as new information becomes available.

Subscription Information/Sample Copies

Remittances and orders for subscriptions, notices of change of address, claims for missing numbers and requests for sample copies should be sent to the Subscription Service Department, Prous Science, S.A., P.O. Box 540, 08080 Barcelona, Spain. Street address: Provenza 388, 08025 Barcelona. Tel. (34-93) 459-2220. Fax (34-93) 458-1535. e-mail: service@prous.es. Please indicate the code number from mailing labels in all correspondence relating to your subscription.

Electronic Databases

Continuously updated information from the print edition of Drugs of the Future is also available in electronic format: on the Prous Science **Ensemble**[®] database; on the **CIPSLINE**[®] diskette-based databases (for use with MDL Information Systems, Inc.'s ISIS[™]/Base software for PC[®] and Macintosh[®] computers); and online via **Dialog file 453** and **DataStar file PRFU**.

For more information on these databases, contact: Marketing Dept., Prous Science, S.A., P.O. Box 540, 08080 Barcelona, Spain. Tel +34 93 459-2220; Fax +34 93 458-1535; e-mail: service@prous.es or Prous Science, Inc., 12th Floor, East Tower, Centre Square, 1500 Market St., Philadelphia, PA 19102, U.S.A. Tel: (215) 246-3441; Fax: (215) 246-3496; e-mail: proussci@aol.com or connect to <http://www.prous.com>.

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Prous Science, S.A., 0377-8282/99, provided that the appropriate fee is paid directly to Copyright Clearance Center (CCC), 222 Rosewood Dr., Danvers, MA 01923, USA, 978-750-8400. For those organizations that have been granted a photocopy license by CCC, a separate system of payment has been arranged. Prior to photocopying items for educational classroom use, please contact CCC.

Copyright ©1999, Prous Science, S.A. Publishers. Reproduction in whole or part is not permitted except by written permission from the publisher.

FIPP Member of the International Federation of Periodical Press.

APP Publication not subject to mandatory control of circulation because advertising pages are less than 10% of the total number of pages.

The Editor has made a reasonable effort to supply complete and accurate information, but does not assume any liability for errors or omissions.
ISSN: 0377-8282 - Depósito Legal: B-154-1.976 - Printed in Spain. - Romargraf, S.A. - Hospitalet de Llobregat (Barcelona)

Progress in the design of inhibitors of coagulation factor Xa

William R. Ewing*, Henry W. Pauls and Alfred P. Spada

Rhône-Poulenc Rorer, Department of Medicinal Chemistry, 500 Arcola Road, Collegeville, PA 19426, USA.

**Correspondence*

CONTENTS

Introduction	771
Background	771
Factor Xa structure and function	774
Affinity labels	775
Transition state analogs	775
Peptide inhibitors	776
Bis-benzamidine inhibitors	777
Benzamidine inhibitors	779
Nonbenzamidine inhibitors	782
Conclusions	783
References	783

Introduction

Myocardial infarction, stroke, deep vein thrombosis and pulmonary embolism accounted for approximately 2 million deaths in the United States in 1996 (1). The formation of an occlusive thrombus is causally related to the pathology of these conditions. As such, antithrombotic therapy is a crucial component in both acute intervention procedures and chronic prevention strategies for treatment and management of these diseases.

Effective antithrombotic therapy often requires administering a combination of antiplatelet and anticoagulant agents. Aspirin and heparin represent the current mainstay of combination therapy for the treatment of coronary syndromes (2). The shortcomings of each have driven intense efforts within the pharmaceutical industry to identify and develop more effective and safer antiplatelet and anticoagulant agents. Significant advances have been made in the development of more potent and effective antiplatelet agents (3, 4); however, the clinical need for improved anticoagulant agents is arguably greater. Current treatment options are limited to unfractionated heparin (UFH), low molecular weight heparins (LMWHs) and warfarin. The challenge remains to achieve consistent, predictable and clinically effective levels of anticoagulation while minimizing the risk of bleeding complications.

Recent approaches to identify anticoagulant agents with improved safety and efficacy have focused on devel-

oping specific inhibitors of enzymes within the coagulation cascade (5). Thrombin remains the most extensively investigated of these targets. Two decades of experience in the design of thrombin inhibitors has led to the development of highly potent and selective inhibitors, several of which have been investigated in large-scale clinical studies (6-10). In general, the results of these studies have fallen short of expectations, demonstrating no clear advantage over heparin in the treatment of coronary syndromes (11). More encouraging clinical results have been obtained in the treatment of venous thromboembolism (12).

Factor Xa inhibitors, the subject of this review, represent a more recent and rapidly evolving approach toward the development of anticoagulant agents. Theoretically, direct inhibition of factor Xa activity should provide a potent anticoagulant devoid of the potentially limiting side effects observed with thrombin inhibitors (5, 13).

Background

To develop superior anticoagulant strategies requires an understanding of the biochemical and biophysical mechanisms activating and regulating blood coagulation. The process of normal hemostasis requires maintaining a delicate balance between the dynamic processes of pro- and anticoagulant activities in circulating blood. Both are governed by a finely tuned and highly integrated cascade of enzymatic processes that amplify the response to vascular injury preventing hemorrhage and initiating the repair processes. An abbreviated scheme highlighting the key aspects of these processes is presented in Figure 1.

Two convergent procoagulant pathways have evolved, each capable of being activated in response to different stimuli. The intrinsic and extrinsic coagulation pathways consist of a cascade composed of serine proteases which effectively amplify the initial stimulus to provide a strong and rapid signal to initiate the coagulation process (14). These pathways ultimately converge upon the formation of factor X and its conversion to factor Xa in the prothrombinase complex.




Fig. 1. Schematic diagram of the enzymatic processes of procoagulant and anticoagulant activities in circulating blood. FXa = factor Xa, PL = phospholipid, TF = tissue factor, TM = thrombomodulin, aPC = activated protein C.

The intrinsic pathway is stimulated by the contact of flowing blood with foreign surfaces or upon vascular injury and exposure of subendothelial matrix collagen (15). Three circulating factors, high molecular weight kininogen, prekallikrein and factor XII, bind together on the surface to yield the catalytically active serine protease, factor XIIa. This branch of the coagulation cascade ultimately produces factor IXa. Factor IXa combines with factor VIIIa, phospholipid, Ca²⁺ and factor X in the intrinsic Xase complex to afford factor Xa.

The extrinsic pathway is initiated following vascular injury and the resulting exposure of tissue factor (TF) onto the surface of endothelial cells and macrophages (16, 17). Tissue factor binds to factor VII and catalyzes its conversion to factor VIIa. This complex, in the presence of Ca²⁺ and phospholipid, converts factor X to factor Xa. Factors XI and IX can also be activated by tissue factor/factor VIIa, thus providing a link with the intrinsic pathway.

Factor Xa, generated by either pathway, combines with the nonenzymatic cofactor Va and Ca²⁺ on the phospholipid surface of platelets or endothelial cells to form the prothrombinase complex. The catalytic activity of factor Xa in this complex is increased 300,000-fold relative to its activity in solution. Factor Xa in the prothrombinase complex converts prothrombin (factor II) by limited proteolysis to release catalytically active thrombin (factor IIa) (18).

Thrombin holds a central position in control of coagulation processes. It catalyzes the cleavage of fibrinogen to fibrin, thus initiating the process of clot formation and

activates factor XIII which cross-links fibrin monomers to stabilize the developing clot. Thrombin binds avidly to fibrin and remains catalytically active within the growing thrombus (19). Thrombin also catalyzes the formation of cofactors Va and VIIIa and thus provides a positive feedback mechanism for its continued generation and the progression of clot development (20). In addition to its direct actions on the coagulation cascade, thrombin is also a potent agonist of platelet activation. The direct activation of platelets is an important first response to maintain normal hemostasis, allowing the generation of a homeostatic plug following injury (20). Prolonged activation and recruitment of platelets will further potentiate the development of clot formation.

Thrombin also plays a key role in the initiation of inhibitory pathways to downregulate the coagulation process. Upon release from the prothrombinase complex, thrombin can bind to thrombomodulin, a glycoprotein present on the surface of endothelial cells (22, 23). Thrombin has high affinity for thrombomodulin which alters its substrate specificity from fibrinogen and the procoagulant factors V, VIII and XIII to protein C. Cleavage of protein C bound to thrombomodulin affords activated protein C. This complex, in the presence of the nonenzymatic cofactor protein S, cleaves the procoagulant cofactors Va and VIIIa, thus providing a mechanism of inactivating the intrinsic coagulation pathway. In addition, active protein C activates the fibrinolytic system by stimulating the release of tissue plasminogen activator from endothelial cell, which provides a physiologically important link between anticoagulant and fibrinolytic pathways (24).

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.